Suzetrigine (Journavx) is an oral, selective Naᵥ1.8 sodium‑channel inhibitor approved by the FDA on January 30, 2025, for moderate-to-severe acute pain (1). It acts peripherally on Naᵥ1.8 channels in nociceptive neurons, avoiding central nervous system side effects associated with opioids (2). Two phase III randomized, double-blind trials in post‑b
Single-incision Laparoscopy for Gastrostomy
407 Reached2 Comments1 Likes
Intestinal Obstruction and Ileocolic Fistula due to Gossypiboma
861 Reached30 Comments15 Likes
Male with Urethral Bleeding due to Insertion of Telephone Wire in Urethra
2465 Reached4 Comments6 Likes
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
Young Girl Presented with Irritability and Abnormal Behavior
2249 Reached11 Comments5 Likes